Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor meetings at the Citizens JMP Life Sciences Conference being held in New York City on May 13-14, 2024. Also, Dr. Patel will join a panel at the Capital One 1st Annual Biotech/Biopharma Disruptors Event being held in New York City on May 14, 2024.
加利福尼亚州纽瓦克/ACCESSWIRE/2024年5月7日/Protagonist Therapeutics, Inc.（“主角” 或 “公司”）（纳斯达克股票代码：PTGX）今天宣布，总裁兼首席执行官迪内什·帕特尔博士将参加2024年5月13日至14日在纽约市举行的Citizens JMP生命科学会议的炉边谈话和投资者会议。此外，帕特尔博士还将参加2024年5月14日在纽约市举行的Capital One第一届年度生物技术/生物制药颠覆者活动的小组讨论。
Citizens JMP Life Sciences Conference - May 13-14, 2024
Citizens JMP 生命科学会议-2024 年 5 月 13-14 日
Format: Fireside Chat
Day/Time: Monday, May 13 at 2:00-2:25 P.M. EDT
Location: New York Hilton Midtown, 1335 Avenue of the Americas, New York
Webcast: Link HERE
格式：炉边聊天
日期/时间：美国东部时间 5 月 13 日星期一下午 2:00-2:25
地点：纽约美洲大道 1335 号纽约中城希尔顿酒店
网络直播：此处链接
If you are interested in meeting with the Protagonist team during the conference, please reach out to your Citizens JMP representative. A replay of the fireside chat will be available for 90 days and published to the Events & Presentations section of the Protagonist corporate website:
如果您有兴趣在会议期间与主角团队会面，请联系您的Citizens JMP代表。炉边谈话的重播将持续90天，并发布到Protagonist公司网站的 “活动与演示” 部分：
Capital One 1st Annual Biotech/Biopharma Disruptors Event - May 14, 2024
Capital One 第一届年度生物技术/生物制药颠覆者活动——2024 年 5 月 14 日
Panel: New Potential Dermatology Treatments for Psoriasis, Urticaria, & Alopecia
Day/Time: Tuesday, May 14 at 2:45-3:45 P.M. EDT
Location: New York City
小组讨论：银屑病、荨麻疹和脱发的新型潜在皮肤科治疗方法
日期/时间：美国东部时间 5 月 14 日星期二下午 2:45-3:45
地点：纽约市
About Protagonist
关于主角
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and JNJ scientists jointly discovered PN-235 (now known as JNJ-2113) as part of Protagonist's Interleukin-23 receptor (IL-23R) collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program. The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension component of Phase 2 is ongoing, as is the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
Protagonist Therapeutics是一家生物制药公司，其基于肽的新化学实体（NCE）rusfertide和 JNJ-2113（前身为 PN-235）处于临床开发的后期3期阶段，均源自该公司的专有技术平台。作为Protagonis与JNJ合作的一部分，Protagonis和JNJ的科学家共同发现了 PN-235（现称为 JNJ-2113），这是Protagonis与JNJ合作的一部分，并随后进行了支持IND的临床前和1期研究，JNJ负责进一步的临床开发。IL-23RRusfertide是天然激素hepcidin的仿制品，是该公司目前处于全球第三阶段开发计划中的主要候选药物。2期REVIVE研究的随机部分已成功完成，结果发表于 这个 新英格兰医学杂志 2024 年 2 月。第二阶段的开放标签扩展部分正在进行中，对真性红细胞增多症中rusfertide的全球3期VERIFY研究也在进行中。根据2024年1月宣布的与武田签订的全球合作和许可协议，正在与武田共同开发Rusfertide并共同商业化。
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at .
有关Proganist、其在研候选药物和临床研究的更多信息，请访问该公司的网站，网址为。
Investor Relations Contact
投资者关系联系人
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
科里·戴维斯博士
生命科学顾问
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
媒体联系人
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061
virginiaamann@ententeinc.com
弗吉尼亚·阿曼，创始人/首席执行官
ENTENTE 公司网络
+1 833 500 0061
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.
来源：Proganist Therapeutics, Inc.
译文内容由第三方软件翻译。